Sredni B, Albeck M, Kazimirsky G, Shalit F
C.A.I.R. Institute, Department of Life Sciences, Bar Ilan University, Ramat Gan, Israel.
Int J Immunopharmacol. 1992 May;14(4):613-9. doi: 10.1016/0192-0561(92)90122-2.
AS101 [ammonium-trichloro (0,0' dioxyethylene)tellurate] is a new immunomodulator shown previously to stimulate the production of various cytokines in vitro and in vivo, and to have minimal toxicity. In the present study we explore the possibility of oral administration of AS101 to mice via cannulation in lieu of interperitoneal or intravenous administration reported to date. Our studies show that oral administration of AS101 at a dose ranging between 50 and 100 micrograms/mouse promotes hemopoietic regeneration after treatment with sublethal doses of cyclophosphamide (CYP) and protects mice from the lethal effects of this compound. In addition, AS101 administered orally confers a strong radioprotective effect upon mice when given before irradiation.
AS101 [三氯(0,0'-二氧乙烯)碲酸铵] 是一种新型免疫调节剂,此前已证明它能在体内外刺激多种细胞因子的产生,且毒性极小。在本研究中,我们探索了通过插管给小鼠口服AS101的可能性,以替代迄今为止报道的腹腔或静脉给药方式。我们的研究表明,以50至100微克/小鼠的剂量口服AS101可促进经亚致死剂量环磷酰胺(CYP)处理后的造血再生,并保护小鼠免受该化合物的致死作用。此外,在照射前口服给予AS101能赋予小鼠强大的辐射防护作用。